News >

Woyach Highlights Long-Term Acalabrutinib/Obinutuzumab Data in CLL

Ellie Leick
Published: Wednesday, Jun 26, 2019

Jennifer A. Woyach, MD

Jennifer A. Woyach, MD

Long-term data with the combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) showcase the efficacy of the regimen in both patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia (CLL), explained Jennifer Woyach, MD. 

“This regimen appears to be very safe, very tolerable over long periods of time, and very effective,” said Woyach, an associate professor at The Ohio State University Comprehensive Cancer Center.

At the 2019 ASCO Annual Meeting, Woyach presented 3-year follow-up data on the combination of acalabrutinib and obinutuzumab in both patients with treatment-naïve and relapsed/refractory CLL.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x